22 Oct
2021

Hub and spoke IP strategies are generating billions of dollars in biopharma

The creation of Radionetics Oncology is just latest sign in recent months of the growth of hub-and-spoke businesses which promise to disrupt IP monetisation in the life sciences

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth